alexa Cardiovascular Diseases on Latin-American People | Open Access Journals
ISSN: 2167-1079
Primary Healthcare: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Cardiovascular Diseases on Latin-American People

Abel Alberto Pavia L*

Department of Hemodynamics and Interventional Cardiology, General Hospital of Mexico, Mexico

*Corresponding Author:
Abel Alberto Pavia L
Chief of hemodynamics and interventional cardiologist
General Hospital of Mexico, Mexico
E-mail: [email protected]

Received date: December 27, 2016; Accepted date: January 12, 2017; Published date: January 19, 2017

Citation: Pavia LAA (2017) Cardiovascular Diseases on Latin-American People. Prim Health Care 7:254. doi:10.4172/2167-1079.1000254

Copyright: © 2017 Pavia LAA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Primary Healthcare: Open Access


It has been estimated that mortality from cardiovascular diseases (CVD) are almost three times more frequent in undeveloped Latin- American (LA) countries that developed countries, and because there were not enough publish data regarding the difference in risk profile of the LA vs. non LA population, the investigators of the CRUCIAL Study planned a sub analysis that could compare the behavior of the proactive interventional strategy in Latin-American vs. Non Latin American countries, as well the differences in the risk profile of the Latin American subjects compare with the rest of the world population included in the study [1-3]. It is also important to remember that the real worldwide behavior of the physicians was to treat Hypertension and Dyslipidemia as separate entities instead to treat cardiovascular risk. And hence The ASCOT Trial in the lipid lowering arm shown a clear benefit in relative risk reduction in mobility and mortality we pretend to address the question trough the design of the CRUCIAL Study to compare in real life the relative reduction in calculated Framingham coronary heart disease risk when a multiple risk factor intervention strategy, based on single-pill amlodipine besylate/atorvastatin calcium was compared with usual care strategy in patients with hypertension and > 3 additional cardiovascular risk factors and base line cholesterol < 6.5 mmol/L and no coronary heart disease [4-6]. It was a 12 month, international. Multicenter, prospective, cluster randomized parallel trial. The results of this study shown that the proactive multifactorial risk factor intervention strategy that simultaneously treat both blood pressure and cholesterol regardless of individual risk factors per se, is more effective in reducing calculated Framingham 10 year CHD risk according the ATP III guidelines. The results of this sub analyses were very important not only because in the intervention group resulted in similar decrease in relative risk reduction in both populations but also shown the difference in basal risk profile. The LA population had an average BMI of 30.4 vs. 28.4 in the non-LA (p>0.001); LA subjects shown a low average HDL levels 42.8 mg/dl vs. Non LA 48.9 mg/dl (P<0.001). In contrast the tobacco consumption was much lower in LA population 29.5% vs. Non LA subjects whose average was 40.8%. Regarding this differences we observed that the relative risk reduction using the Framingham score was similar in the multiple risk factor intervention strategy. Besides the ASCOT trial, the Cards Study and the Heart Protection Study demonstrated that a decrease in 1 mmol LDL Cholesterol reduce cardiovascular events and the ACC/AHA guidelines published in 2014 recommended moderate statin doses in this kind population. Hopefully this concept will improve the primary prevention of CVD worldwide including higher risk population as LA countries [7-9].


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 335
  • [From(publication date):
    March-2017 - Aug 23, 2017]
  • Breakdown by view type
  • HTML page views : 297
  • PDF downloads :38

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version